Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
RIPR
- Cancer Type
- Gastrointestinal, Gastrointestinal Stromal Tumours
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
Exceptional Access Program ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
- Drugs Used
- ripretinib
Regimen Monograph
Dec 2025
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 27, 2026
